Greenwich LifeSciences In... (GLSI)
8.94
0.10 (1.13%)
At close: Apr 17, 2025, 3:59 PM
8.75
-2.12%
After-hours: Apr 17, 2025, 07:41 PM EDT
Company Description
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.
Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018.
Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Greenwich LifeSciences Inc.
| Country | United States |
| IPO Date | Sep 25, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Eric Rothe |
Contact Details
Address: Building 14 Stafford, Texas United States | |
| Website | https://greenwichlifesciences.com |
Stock Details
| Ticker Symbol | GLSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001799788 |
| CUSIP Number | 396879108 |
| ISIN Number | US3968791083 |
| Employer ID | 20-5473709 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christine T. Fischette Ph.D. | Vice President of Business Development |
| Dr. Jaye L. Thompson Ph.D. | Vice President Clinical & Regulatory Affairs |
| Eric Rothe | Founder & Independent Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2025 | 10-K | Annual Report |
| Apr 08, 2025 | 4 | Filing |
| Apr 07, 2025 | 4 | Filing |
| Mar 31, 2025 | NT 10-K | Filing |
| Jan 13, 2025 | 4 | Filing |
| Jan 08, 2025 | 4 | Filing |
| Jan 07, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Jan 02, 2025 | 4 | Filing |